Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BeyondSpring Inc. (BYSI : NSDQ)

• Company Description    BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. Number of Employees: 40

• Price / Volume Information    Yesterday's Closing Price: $2.21 Daily Weekly Monthly 20 Day Moving Average: 134,718 shares Shares Outstanding: 40.32 (millions) Market Capitalization: $89.10 (millions) Beta: 0.17 52 Week High: $3.44 52 Week Low: $0.98 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.95% -14.59% 12 Week 82.64% 58.33% Year To Date 35.58% 28.09%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 CAMPUS DRIVE WEST SIDE 4TH FLOOR SUITE 410 - FLORHAM PARK,NJ 07932 USA ph: 646-305-6387 fax: 646-882-4228 ir@beyondspringpharma.com http://www.beyondspringpharma.com

• General Corporate Information    Officers Lan Huang - Chief Executive Officer and Director Brendan Delaney - Director Patrick Fabbio - Director Matthew Kirkby - Director Jiangwen Majeti - Director Peer Information BeyondSpring Inc. (CORR.) BeyondSpring Inc. (RSPI) BeyondSpring Inc. (CGXP) BeyondSpring Inc. (BGEN) BeyondSpring Inc. (GTBP) BeyondSpring Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G10830100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 40.32 Most Recent Split Date: (:1) Beta: 0.17 Market Capitalization: $89.10 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - 2.49 12/31/24 - 2.60 Quick Ratio 06/30/25 - - 03/31/25 - 2.49 12/31/24 - 2.60 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - -0.31 12/31/24 - -0.37 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©